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ABSTRACT
Schistosomiasis is an infectious tropical disease caused by parasitic flatworm of the genus
Schistosoma. This debilitating disease chronically infects about 200 million people globally and man-
agement relies on chemotherapy. Unfortunately, the solely available schistosomicide (praziquantel)
against all forms of adult schistosmes has been faced with numerous drawbacks. Thus, there is an
urgent need to design and develop a new regimen for schistosomiasis. In light of this, the current
study focuses on inhibiting the schistosome glucose transporter 4 (SGTP4) as a therapeutic candidate
for schistosomiasis. Several studies have revealed that Schistosoma parasites require an adequate
amount of energy/glucose to survive. We modelled the 3D structure and subsequently used the hom-
ology model for docking with praziquantel (PZQ), Licochalcone A, Licarin and Harmonine. The docked
complexes were subjected to molecular dynamics using Desmond system of Schrodinger software.
Furthermore, the pharmacokinetic parameters of the ligands were investigated using the QikProp tool
in the Schrodinger-2019-4 software suite. After performing all the computational analysis, our findings
reveal that all four ligands were able to inhibit SGTP4 effectively through the higher glide G score
(dock score) of 5.8 (5.8), 6.5 (6.4), 7.3 (7.3) and 4.9 (4.9) in kcal/mol for praziquantel, lico-
chalcone A, licarin and harmonine respectively against the protein. The molecular simulation further
confirmed that the stability of the complexes formed between the ligands and protein is excellent.
More so, all the ligands fulfilled oral drugability of both the Lipinski’s rule of five and Veber’s rules.
The findings in this present study provide new useful insights for the design of drugs which can serve
as an alternative to praziquantel in the treatment of schistosomiasis through the inhibition of SGTP4.
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For many decades, schistosomiasis continues to be on a swift
and rapid increase globally, claiming thousands of lives per
annum and leaving over 800 million persons at risk of infec-
tion (WHO, 2020). Currently, it’s the second most prevalent
among the groups of neglected tropical diseases (NTDs),
which are acute and chronic infectious diseases that have
been forsaken for many years (Adekiya et al., 2020a).
Schistosomiasis is caused mainly by Schistosoma mansoni (S.
mansoni), S. haematobium and S. japonicum. It has been
reported that the disease poses a great negative impact on
agricultural produces and severe effects on pregnant women
and the development and life of school children in affected
regions (Adekiya et al., 2017). This disease has been reported
to be under the group A causing agents of several cancer
types such as; liver, bladder, intestine among others, the co-
infection has also been reported with other chronic ailments
such as HIV-AIDS. Over the years, PZQ remains the only drug
of choice and the best therapeutic agent due to its
effectiveness against all forms of schistosomes (Aruleba
et al., 2019). This drug is very cheap, easily accessible and
possesses lesser side effects which are tolerable in patients
of all ages. Sadly, some shortcoming has been reported on
PZQ, some of which include; rapid metabolism, which
reduces the bioavailability of the drug in the circulation,
drug resistance in some parts of the world, ineffectiveness
against the younger forms of the schistosomes worm and
unable to prevent the reinfection of schistosomiasis (Aruleba
et al., 2019) hence, the need for an alternative
drug molecule.
In recent times, the use of a computational approach has
been a great technique in medicinal chemistry for the
screening and evaluation of novel drug molecular com-
pounds capable of interacting with specific molecular recep-
tors. Thus, the interaction of some selected potential anti-
schistosomal compounds (Licochalcone A, Licarin, Harmonine
and praziquantel as control) was investigated on one of the
prominent targeted protein found in the tegument of
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Schistosoma species. Recently, Adekiya et al. (2020b) high-
lighted several potential druggable and vaccine proteins tar-
gets and molecular receptors found on the surface of the
schistosome tegument such as; schistosome glucose trans-
porter 1 (SGTP1) and 4 (SGTP4) which are found in all types
of schistosomes (Skelly et al., 1994, 1998), acetylcholinester-
ase (AChE) and a nicotinic type of acetylcholine receptor
(nAChR) which are primarily located on the surface of male
schistosomes (MacDonald et al., 2014; Mansour & Mansour,
2002). Other targeted protein found on the surface of the
tegument is dynein (S. mansoni) (Mansour & Mansour, 2002).
For the purpose of this study, SGTP4 was the target protein
because, SGTP4 transporter protein is distributed evenly on
the ventral and dorsal surfaces of male and female schisto-
some teguments, which has a unique double lipid bilayer
structure (Mansour & Mansour, 2002). Several studies have
revealed that Schistosoma parasites require an adequate
amount of energy/glucose to survive (Krautz-Peterson et al.,
2010; Skelly & Shoemaker, 1996; Skelly et al., 1994, 1998).
This glucose/energy is first taken up by the tegument of the
schistosomes and not by the caecum of the intestine, and its
uptake inside the tegument of the schistosomes are facili-
tated by the help of the schistosome glucose transporters,
which are found in schistosome tegument (Krautz-Peterson
et al., 2010). The distinctive location of the SGTP4 on the
membrane tegument indicates that the protein happens to
be the transporter that facilitates the movement of glucose
from the host bloodstream into the parasite tegument
(Skelly & Shoemaker, 2001). Furthermore, SGTP4 controls the
developmental stages and appear during the transformation
of free-living cercariae into schistosomula during growth
where it fulfils the needs of the parasites for the high uptake
of glucose once they enter the human-host (schistosomula
stage) and throughout adulthood (Skelly & Shoemaker,
1996). Thus, this study evaluates the several aspects behind
the anti-schistosomal activity of Licochalcone A, Licarin,
Harmonine against SGTP4 protein receptor. Moreover, prazi-
quantel, a standard and the only drug of choice for schisto-
somiasis treatment was docked against SGTP4 protein
receptor for comparison.
2. Materials AND methods
2.1. Homology modelling and preparation of SGTP4 as
a drug target
The SGTP4 sequence was retrieved in FASTA format from the
Uniprot database with accession no Q26581_SCHMA.
Thereafter, the suitable template for homology modeling
was identified by performing a blast search on protein data
bank (PDB) since the crystal structure of the SGTP4 is not
available on the PDB. The solute carrier family 2, facilitated
glucose transporter member 3 (4ZW9: A) was identified and
the sequence was used to model the 3D structure of SGTP4
using the Schrodinger Suite. The target and the template
were aligned and all other PRIME parameters were adjusted
accordingly. Loops were refined and subsequently, the
refined homology model was utilized for downstream steps.
The structure was opened using the protein preparation
wizard in Maestro and using a method described by Fadaka
et al. (2019) we optimized PropKa, generated the het states
using EPIK, alleviated steric clashes by force field: OPLS_2005
and PRIME was used to fix missing atoms. Finally, the stabil-
ity and overall quality of the homology modelled structure
of the SGTP4 was assessed using RAMPAGE (Laskowski
et al., 1996).
2.2. Ligands selection and preparation as inhibitors
of SGTP4
In this study, we used five ligands that have been reported
in literature as schistosomicide or potential schistosomicide.
Amongst the five ligands, praziquantel (pubchem ID-4891)
was used as our control because it is the only available
chemotherapy active against all forms of adult Schistosoma
spp. and other ligands retrieved from pubchem (Kim et al.,
2019) are licochalcone A (pubchem ID-5318998), licarin (pub-
chem ID-73548) and harmonine (pubchem ID-14825482). Of
course, removing salt and additional hydrogen atoms are key
to obtaining good and reliable protein-ligand docked com-
plex. Hence, all ligands in their 3-D structure format were
subjected to ligand preparation (LigPrep) of the Schrodinger
Maestro suite. They were optimized via Epik 25 in pH
between 7± 2 and ring conformation, desalting, sterochemis-
tries and tautomer generation were selected to get at least
32 conformations for each ligand.
2.3. Admet/tox screening
In the drug discovery platform, identification of new mole-
cules with sort after pharmacokinetic and ADME/Tox profile
is a challenge. Hence, the prediction of these properties
using computational techniques is considered a vital step in
the screening for a new tolerable compound with little or no
effects on the body (Akabli et al., 2019). The pharmacokinetic
parameters of the ligands (praziquantel, licochalcone A,
Licarin, Harmonine) were investigated using the QikProp tool
in the Schrodinger-2019-4 software suite. Subsequently, we
forecasted the toxicological properties of the selected ligands
using admetSAR online device (http://lmmd.ecust.edu.cn/
admetsar1/predict/) to ascertain if they fulfilled the Lipinski’s
and Veber rules (Lipinski et al., 2001; Veber et al., 2002). And
here, we predicted the acute oral toxicity, carcinogenic prop-
erties, ames toxicity and rodent acute toxicity.
2.4. Generation of grid and molecular docking of SGTP4
against the ligands
The generation of the receptor grids is vital as it identifies
the binding area between a ligand and the receptor. The
receptor grid generation application of the maestro version
12.2 was used to define the active binding site in terms of
coordinates x, y and z by indicating the amino acid residues
which have been reported previously for the protein. Here,
the receptor grid box resolution was centered at coordinates
20.57 (x-axis), 18.10 (y-axis), and 26.99 (z-axis). After suc-
cessfully generating the grid, we performed molecular
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docking on the prepared receptor against each of the four
ligands using the Glide tool in Maestro. All ligands were first
docked unto the active site of SGTP4 using standard preci-
sion (SP) and followed by extra precision (XP) to decrease
the intermediate conformations. The interaction diagram of
the ligands with amino acid residues at the active site of the
SGTP4 was visualized using the ligand interaction tool.
2.5. Prime molecular mechanics, the generalized born
solvent accessibility (MM-GBSA) calculation
The binding free energies (DGbind) of the docked complexes
were calculated using the MM-GBSA method, implemented
in Schrodinger suite software. This post docking tool is cru-
cial because it aids the prediction of relative free binding
energy with an acceptable level of accuracy and provides
the correct ranking of ligands binding (Lyne et al., 2006).
Here, the PRIME module embedded in Maestro was
employed to ascertain the free binding energies of the
docked complexes obtained from the XP docking step.
Briefly, the energies of the various complexes were calcu-
lated using the OPLS_2005 force field in relation to GBSA
continuum model.
2.6. Molecular dynamics simulation
All the docked complexes were subjected to molecular
dynamics (MD) using Desmond system builder panel in
Schrodinger with OPLS 2005 force field and each complex
was restricted with a predefined TIP3P water molecule in
orthorhombic box (Jorgensen et al., 1983). Subsequently, the
box was reduced and the ligand-receptor complex was neu-
tralized by adding sodium and chloride ions. The system was
equilibrated at constant temperature (300 Kelvin) and stand-
ard atmospheric pressure (1.01325 bar) using methods by
Hoover thermostat and Martyna-Tobias-Klein barostat
(Essmann et al., 1995; Hoover, 1985). The long-range electro-
static interactions were determined by Particle-Mesh-Ewald
method (Hoover, 1985). The RMSD plots for backbone atoms
were analyzed to identify the relative stability of the ligand
in the binding pocket of the receptor.
3. Results and discussion
The urgent need for a new schistosomicide cannot be over-
emphasized due to challenges faced by the sole available
PZQ. Designing a structure-based drug with high efficacy
could elude these problems faced by the existing drug.
Indeed, conventional methodologies employed in the identi-
fication and development of inhibitors are capital and time-
consuming, hence, computational techniques have been
used and gained importance in recent years (Adekiya et al.,
2017; Aruleba et al., 2018, 2020; Fadaka et al., 2020; Ojo
et al., 2019; Oyinloye et al., 2019).
3.1. Homology modelling
Due to the unavailability of the resolved 3-D structure of the
SGTP4 protein in PDB, we generated one through homology
modelling using BLAST P against existing structures in the PDB.
The crystal structure of 4ZW9: A was identified and selected
with a sequence similarity of 37.83% with the SGTP4 protein
sequence (Figure 1). And it has been documented that a
sequence similarity greater than 25% is needed to perform
homology modelling (Yadav & Khandelwal, 2019).
Subsequently, modelling was performed using the PRIME mod-
ule of the Schrodinger suite and depicted in Figure 2A is the
modelled structure of the SGTP4 protein and the superimposed
of the template. The homology structure was subjected to
refinement by the Protein Prep wizard in Maestro (Figure 2b).
In essence, this is done to stabilize the protein by the addition
of hydrogen bond, optimize the structure and minimize the
energy. Furthermore, the quality of the modelled SGTP4 was
validated using PROCHECK, a program for structure verification
that relies on principle on Ramachandran plot (Aruleba et al.,
2018). The results (Figure 2c) reveal that the structure has
93.2% amino acid residues in the most favoured regions, a total
of 6.6% residues in both additional and generously allowed
regions and 0.2% residues in the disallowed regions. This signi-
fies that the built model is of a high quality due to the excellent
distribution of amino acids in the allowed regions.
3.2. Docking
The binding affinity between all the potential anti-schistoso-
mal molecules and SGTP4 protein was evaluated by in silico
molecular docking analysis. The three-dimensional structure
Figure 1. Alignment step of SGTP4 sequence with template (4zw9: A) Coloured by default.
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of all the druggable molecules was retrieved in 3D sketcher
and imported into the Schrodinger Maestro suite workplace
for preparation and optimization (Figure 3a–d), at least, 32
conformers for each ligand was generated. Subsequently, the
ligands were subjected to docking with the active site of
SGTP4, using SP and thereafter, XP in order to decrease the
intermediate conformations. The 2D docking poses of all the
best ligand conformers interaction with the active site of
SGTP4 shown in Figure 4, were visualized with the help of
ligand interaction tool. Here, results were described in terms
of Glide score, Dock score, free binding energy and number
of H-bonds. Glide score showed that all the five ligands were
energetically favorable in a similar trend (Table 1). However,
praziquantel (a standard drug for schistosomiasis) have a
glide binding score of 5.8 Kcal/mol against SGTP4 but, do
not generate hydrogen bond interaction with any amino
acids of the protein receptor. Licochalcone A isolated from
Glycyrrhiza inflate increased reactive oxygen species in adult
S. mansoni which acted on the tegument, mitochondrial and
cellular membrane of the worm thereby inducing death of
the parasite (Souza et al., 2017). In view of licochalcone A
anti-schistosomal potentials, we docked it against SGTP4 and
it showed a better binding score of 6.5 Kcal/mol when
compared to the control; praziquantel, with an essential
interaction with Asn 292, which is important for the inhib-
ition of SGTP4. More so, licarin A a neolignan isolated from
different plant species was utilized here based on reported
activity against S. mansoni (Meleti et al., 2020; Pereira
et al., 2011).
The docking of licarin against SGTP4 showed good bind-
ing interaction of 7.3 Kcal/mol, but unfortunately, the lig-
and does not display any hydrogen bond interaction with
any essential amino acids present in SGTP4 protein, which
may be of importance for the inhibition or regulation of the
protein. It was further revealed in our docking study that
harmonine showed the least binding score of 4.9Kcal/mol,
but interestingly, displayed an important interaction with Glu
38, Asn 34 and Thr 296 of the protein. We selected harmo-
nine based on results reported by Kellershohn and co-work-
ers (Kellershohn et al., 2019) that it caused physiological,
Figure 2. Modeled structure of SGTP4 using 4ZW9: A template. Modeled (A), prepared protein (B), and quality check (C).
Figure 3. Prepared 3D structures of the ligands. Praziquantel (control)-ID:4891 (A), Licochalcone A-ID:5318998 (B), Licarin-ID:73548 (C), Harmonine-ID:14825482 (D).
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cellular and molecular changes like gut dilation, tegumental
damage, impaired fecundity and reduced motility on S. man-
soni. Thereafter, the MM-GBSA free energy calculations were
used to evaluate the free binding energies of the ligands
inside the SGTP4 active site. It was revealed that licarin
(-69.40 kcal/mol) and harmonine (-85.31 kcal/mol) had a bet-
ter MM-GBSA score than the PZQ (-64.39 kcal/mol).
Nevertheless, licochalcone A had a relatively lower MM-GBSA
value of 62.74 kcal/mol than PZQ.
3.3. Analysis of molecular dynamics simulations
MD simulations were used to calculate the docking results
using the Desmond package in Schrodinger with OPLS
2005 force field and each complex was restricted with a
predefined TIP3P water molecule in the orthorhombic box.
The behaviour of the atomic positions of all the molecular
compound interaction with the SGTP4 protein from the
root mean square deviation (rmsd) (Figures 5a–8a) were
studied and it was shown that there is no large variation in
the binding simulation of compounds to the receptor. Thus,
these results are in accordance with the docking results
which showed that all the compounds depicted good glide
binding score with the SGTP4 protein apart from licochal-
cone A and licarin which showed slightly noticeable differ-
ent atomistic behaviour (Figures 6a and 7a). However, the
binding stability of all the compounds to the SGTP4 protein
receptor could be depicted by the smaller variations of the
rmsd. As shown in the RMSF results in Figure 5b–8b, there
Figure 4. 2D docking interactions. Polar, hydrophobic and charged interacting residues. Praziquantel (A), Licochalcone A (B), Licarin (C), Harmonine (D).
Table 1. Docking results of the ligands and the energy generated in the active sites of the receptors.
Receptor Glide Gscore Dock score DGbind (kcal/mol) (No) of H-bonds within 2.5 Å
Praziquantel 5.8 5.8 64.39 /
Licochalcone A 6.5 6.4 62.74 (1) ASN292
Licarin 7.3 7.3 69.40 /
Harmonine 4.9 4.9 85.31 (3) GLU38 ASN34 THR296
Figure 5. MD simulations: (A) Root mean standard deviation(RMSD) of Praziquantel with modeled SGTP4 complex as a function of 50 nanoseconds simulation
time, (B) Root mean square fluctuation (RMSF) values of complex SGTP4 residues with Praziquantel, and (C) The SGTP4- Praziquantel contacts.
JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS 5
was deviation of different residues of SGTP4 when com-
pared to the chosen reference molecule. Hence, both the
RMSF and RMSD ligands showed consistent behaviour
throughout the simulation period, this could further infer
stability of the complexes.
The location of the binding or the interaction of the
molecular compounds and SGTP4 was also evaluated by
counterpart MD modelling. Interestingly, the MD results
showed that all the compound interaction with the SGTP4
protein has a water bridge, hydrophobic, hydrogen inter-
action. Praziquantel; the control has contact hydrogen bond
interaction with SGTP4 at residue GLN 313, while the drug
formed water-bridge with the protein at residues TYR 176
and VAL 316. Praziquantel, the control drug has hydrophobic
interaction at protein residues LEU 35, ILE 172, TYR 176, ILE
295 ILE 312 and VAL (Figure 5c), it was discovered that there
are lesser contact interactions between praziquantel and
SGTP4 when compared with all the potential anti-schistoso-
mal compounds evaluated in this study. As shown in Figure
6c, we discovered a hydrophobic interaction between the
licochalcone A and SGTP4 in protein residues LEU 30, LEU
35, ARG 130, ILE 295 and VAL 316. Hydrogen bonding was
observed in TYR 176, GLN 313, ASN 427 and ASN 292, which
was also seen in the docking results. There was significant
Figure 6. MD simulations: (A) Root mean standard deviation (RMSD) of Licochalcone A with modeled SGTP4 complex as a function of 50 nanoseconds simulation
time, (B) Root mean square fluctuation (RMSF) values of complex SGTP4 residues with Licochalcone A, and (C) The SGTP4-Licochalcone A contacts.
Figure 7. MD simulations: (A) Root mean standard deviation(RMSD) of Licarin with modeled SGTP4 complex as a function of 50 nanoseconds simulation time, (B)
Root mean square fluctuation (RMSF) values of complex SGTP4 residues with Licarin, and (C) The SGTP4- Licarin contacts.
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water molecule bridges at protein residues THR 296, SER
299, GLN 313 and ASN 427.
Markedly, licarin which does not show any interactions
with SGTP4 protein residues in docking result showed signifi-
cant hydrogen bonding interactions at residues ASN 34 and
ILE 172 in MD (Figure 7c). Furthermore, the ligand showed
hydrophobic interactions at protein residues LEU 35, TYR
176, ILE 295, LEU 302, and LEU 309 to VAL 316, while water-
assisted interactions were seen in residues ASN 34, ILE 172,
SER 175, ILE 295, and THR 296 to SER 299. As shown in
Figure 8c, harmonine showed significant hydrogen bonding
between the ligand and SGTP4 protein at residues LEU 30,
LEU 35, ASN 292, ASN 427, the hydrogen contact to residues
ASN 34, GLU 38 and THR 296 are also shown by the docking
results. The hydrophobic interaction of the ligand with
SGTP4 protein is found in LEU 30, LEU 35, LEU 168 to TYR
176, ILE 295, and VAL 316 to PHE 391, while ASN 29, LEU 30,
LEU 35, SER 73, ASN 292, ILE 295, GLN 313, LYS 315 and ASN
427 are the protein residues that formed water bridge inter-
actions with SGTP4. More so, notable interactions for the
water molecule bridges which are significant for the water-
assisted ionic contacts between the ligand and the receptor
are found in ASN 34, GLU 38 and THR 296, which corre-
sponded with what was seen in the docking results.
3.4. Oral bioavailability (ADME) analysis
The failure of RO5 by a drug molecular compound does not
depict its efficacy in treating certain diseases, but there is a
high tendency of encountering an oral activity problem. And
meeting the criteria of RO5 does not guarantee the drug-
likeness of the compound, because RO5 says nothing about
the specific chemistry structural characteristics embedded in
non-drugs or drug compounds (Lipinski, 2004). Although,
90% of orally active drug molecule which has bypassed the
second phase of clinical trials, met the physicochemical par-
ameter ranges of RO5 orally active molecular compound cri-
teria, which are; log p 5, MWT  500, H-bond acceptors 
10, H-bond donors  5 (Lipinski, 2004; Lipinski et al., 2001).
These physicochemical parameters are usually associated
with intestinal permeability and acceptable aqueous solubil-
ity as well as the steps one in oral bioavailability (Ojo et al.,
2020). However, the RO5 of the molecular drug compounds
used in this study was evaluated, and it was shown (Table 2)
that licochalcone A, licarin, harmonine and praziquantel
meet all the oral drugability and bioavailability of Lipinski’s
rule of five criteria. Praziquantel was predicted to meet all
the criteria of the RO5 for an orally active drug molecule.
Subsequently, the Veber’s rule which predicted the oral
drugability of a molecular compound by meeting the follow-
ing criteria; rotatable bond value less than or equal to 10,
hydrogen bond donors and acceptors less than or equal 12,
and the topological polar surface area not greater than 140
Å2 was further used to predict the oral bioavailability of the
compounds. The Veber’s rule also buttressed the results pre-
dicted by the RO5 that is, licochalcone A, licarin, harmonine
and praziquantel; the control for orally active drug molecule.
As aforementioned, RO5 does not say anything about the
specific chemistry, structural properties of a compound and
does not depict its efficacy in disease treatment, rather
Figure 8. MD simulations: (A) Root mean standard deviation(RMSD) of Harmonine with modeled SGTP4 complex as a function of 50 nanoseconds simulation time,
(B) Root mean square fluctuation (RMSF) values of complex SGTP4 residues with Harmonine, and (C) The SGTP4-Harmonine contacts.






MW HBA HBD Log p nRB TPSA
ROF cut-off < 500 < 10 < 5  5  1  10  140
Praziquantel 312.41 2 0 2.40 0 2 40.62 Å2
Licochalcone A 338.40 4 2 3.98 0 6 66.76 Å2
Licarin 326.39 4 1 3.88 0 4 47.92 Å2
Harmonine 282.51 2 2 4.72 0 15 40.62 Å2
Note: ROF: Lipinski’s Rule of Five; MW: Molecular weight (g/mol); HBA:
Hydrogen bond acceptor; HBD: Hydrogen bond donor; Log P: Lipophilicity;
nRB: Number of rotatable bond; TPSA: Topological polar surface area.
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predict the oral bioavailability and intestinal permeability.
Perhaps, if any compounds used in this study fails the oral
bioavailability evaluation when the potency of the com-
pound in treating schistosomiasis is finally ascertained
experimentally, it could be delivered using a nanomedicine
approach, which uses the application of nanotechnology
(advanced drug delivery systems (DDS) and targeted
approach). An approach used for monitoring, treatment, con-
trol and prevention of biological diseases and has been
promising in improving pharmaceutical ingredients in the
treatments of several diseases (Adekiya et al., 2020b).
Alternatively, it could be administered using other routes of
molecular active compound administration, such as intraven-
ous, intramuscular among others.
4. Conclusion
Due to the challenges faced by PZQ, studies in the last few
years have investigated various natural products from differ-
ent chemical classes for their anti-schistosomal effect. In the
current study, various computational approaches were
employed to inhibit the activity of SGTP4; a druggable pro-
tein found on the surface of the schistosome tegument. The
binding affinity and stability of the binding of four identified
ligands against SGTP4 were similar to that of PZQ. Thus, pro-
viding a new avenue for schistosomiasis remedy by fast-
tracking the drug discovery process. Overall, further experi-
mental validations are needed to have a deeper insight into
how these ligands will elicit their inhibitory activities
on SGTP4.
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